Immune status before first and second islet infusion according to insulin need at 6 months posttransplantation among recipients receiving two islet grafts
| At posttransplant month 6 | P* | ||
|---|---|---|---|
| Insulin independent | Insulin dependent | ||
| n | 8 | 9 | |
| Grafts | |||
| Immune status before ATG | |||
| Total lymphocyte count | 1,567 (1,044–2,023) | 2,065 (1,906–2,721) | 0.03 |
| CD3+ count (cells/mm3) | 1,134 (839–1,328) | 1,419 (1,189–1,761) | 0.07 |
| CD19+ count (cells/mm3) | 223 (119–255) | 267 (225–430) | 0.04 |
| Leucocyte count | 5,250 (3,950–6,925) | 6,400 (5,700–8,400) | 0.08 |
| Presence of T-cell reactivity against IA2 and/or GAD | 5/12 | 7/12 | 0.57 |
| Positivity for ICA/GAD/IA2-A | 3/5/2 | 1/4/4 | NS |
| Positivity for two or more autoantibodies | 3 | 2 | 0.62 |
| Immune status at first infusion | |||
| Total lymphocyte count | 189 (97–584) | 272 (154–779) | 0.25 |
| CD3+ count (cells/mm3) | 27 (12–134) | 52 (12–80) | 1.0 |
| Leucocyte count | 3,350 (2,525–7,700) | 8,700 (2,725–13,350) | 0.29 |
| Immune status before second infusion | |||
| Total lymphocyte count | 499 (357–593) | 636 (501–833) | 0.15 |
| CD3+ count (cells/mm3) | 186 (169–267) | 277 (224–341) | 0.05 |
| CD19+ count (cells/mm3) | 213 (84–269) | 182 (152–311) | 0.50 |
| Leucocyte count | 3,150 (2,250–3,825) | 3,900 (3,300–4,900) | 0.08 |
| Presence of T-cell reactivity against IA2 and/or GAD | 2 | 3 | 0.62 |
| Positivity for ICA/GAD/IA2-A | 1/5/2 | 1/6/4 | NS |
| Positivity for two or more autoantibodies | 2 | 3 | 0.62 |
Data are median (IQR).
*Statistical analysis was done with Mann-Whitney U test for continues variables, Fisher exact test for dichotomous variables. NS, not significant.